PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer

Treatment of triple-negative breast cancer (TNBC) remains an unmet clinical need owing to its lack of an efficient therapeutic target. The targeting of DNA repair by poly(ADP-ribose) polymerase (PARP) inhibitors has shown benefit for patients with the BRCA variation. However, sensitivities to the PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Wen-Jing, Chen, Cheng-Hsun, Chang, Yu-Chu, Cheng, Chia-Hsiung, TsaI, Ying-Huei, Lin, Cheng-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539542/
https://www.ncbi.nlm.nih.gov/pubmed/34683150
http://dx.doi.org/10.3390/jpm11101009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539542/
https://www.ncbi.nlm.nih.gov/pubmed/34683150
http://dx.doi.org/10.3390/jpm11101009

Ejemplares similares